AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment
AstraZeneca recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast cancer. Over the last week, AstraZeneca's share price increased by 1%, aligning closely with the broader market's growth of 2%. While the company's recent product developments, including trials for ENHERTU and IMFINZI, and collaborations like the partnership with Danaher Corporation, underscore its innovation in oncology, these advancements likely added some weight to the overall market trend rather than significantly influencing the stock's performance in isolation.
We've discovered 3 weaknesses for AstraZeneca that you should be aware of before investing here.
The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
The recent news regarding AstraZeneca's advancements in oncology, including promising trial results for ENHERTU, may bolster their narrative of growth through innovation. These developments, alongside strategic collaborations, have the potential to enhance future revenue streams and earnings. While the 1% share price increase aligns with recent market trends, the longer-term picture reveals a more substantial total shareholder return of 44.76% over the past five years. During this period, AstraZeneca has demonstrated resilience, with performance reflected in their strategic expansions and R&D efforts.
Within the last year, AstraZeneca did not match the broader UK market, which outperformed it with a 3.5% return compared to AstraZeneca's own performance. This highlights the importance of the company's strategic initiatives and their impact on maintaining competitiveness, particularly against market or industry trends.
Looking forward, the news on ENHERTU and other developments might influence revenue and earnings projections positively. Analysts predict a 5.9% annual growth in revenue over the next three years, reaching $65.3 billion with earnings potentially hitting $13.5 billion by 2028. This growth trajectory could align with AstraZeneca's estimated fair value of £133.57, which marks a 19.7% increase from the current share price of £107.28. The consensus price target indicates potential upside, although it's crucial to consider prospective risks such as competitive pressures and regulatory changes.
Click here to discover the nuances of AstraZeneca with our detailed analytical financial health report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LSE:AZN.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Rosemary has been linked to better memory, lower anxiety and even protection from Alzheimer's
Rosemary (Rosmarinus officinalis), the aromatic herb native to the Mediterranean, has long been treasured in kitchens around the world. But beyond its culinary charm, rosemary is also gaining recognition for its impressive health benefits, especially when it comes to brain health, inflammation and immune function. Research suggests rosemary may even hold promise in the fight against Alzheimer's disease, the leading cause of dementia worldwide. Historically, rosemary has been linked to memory and mental clarity. In ancient Greece and Rome, students and scholars used rosemary in the hope of sharpening concentration and recall. Modern science is finding there may have been something in this: in one study, people who inhaled rosemary's scent performed better on memory tasks compared to those in an unscented environment. So how does rosemary work on the brain? There are several mechanisms at play. For starters, rosemary stimulates blood circulation, including to the brain, helping deliver more oxygen and nutrients, which may improve mental clarity. It also has calming properties; some studies suggest its aroma can reduce anxiety and improve sleep. Lower stress can mean better focus and memory retention. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Rosemary contains compounds that interact with the brain's neurotransmitters. One such compound, 1,8-cineole, helps prevent the breakdown of acetylcholine, a brain chemical essential for learning and memory. By preserving acetylcholine, rosemary may help support cognitive performance, especially as we age. Another bonus? Rosemary is packed with antioxidants, which help protect brain cells from damage caused by oxidative stress – a major factor in cognitive decline. Rosemary is rich in phytochemicals, plant compounds with health-enhancing effects. One of the most powerful is carnosic acid, an antioxidant and anti-inflammatory agent that helps shield brain cells from harm, particularly from the kinds of damage linked to Alzheimer's disease. Read more: In 2025, researchers developed a stable version of carnosic acid called diAcCA. In promising pre-clinical studies, this compound improved memory, boosted the number of synapses (the connections between brain cells), and reduced harmful Alzheimer's related proteins like amyloid-beta and tau. What's especially exciting is that diAcCA only activates in inflamed brain regions, which could minimise side effects. So far, studies in mice show no signs of toxicity and significant cognitive improvements – raising hopes that human trials could be next. Researchers also believe diAcCA could help treat other inflammatory conditions, such as type 2 diabetes, cardiovascular disease and Parkinson's disease. Rosemary's benefits could extend well beyond the brain. It's been used traditionally to ease digestion, relieve bloating and reduce inflammation. Compounds like rosmarinic acid and ursolic acid are known for their anti-inflammatory effects throughout the body. Rosemary may even benefit the skin – a review suggests it can help soothe acne and eczema, while carnosic acid may offer anti-ageing benefits by protecting skin from sun damage. Rosemary oil also has antimicrobial properties, showing promise in food preservation and potential pharmaceutical applications by inhibiting the growth of bacteria and fungi. For most people, rosemary is safe when used in food, teas or aromatherapy. But concentrated doses or extracts can pose risks. Consuming large amounts may cause vomiting or, in rare cases, seizures – particularly in people with epilepsy. There's also a theoretical risk of rosemary stimulating uterine contractions, so pregnant people should avoid high doses. Because rosemary can interact with some medications – such as blood thinners – it's best to check with a healthcare provider before taking large amounts in supplement form. Rosemary is more than just a kitchen staple. It's a natural remedy with ancient roots and modern scientific backing. As research continues, particularly into breakthrough compounds like diAcCA, rosemary could play an exciting role in future treatments for Alzheimer's and other chronic conditions. In the meantime, adding a little rosemary to your life – whether in a meal, a cup of tea, or a breath of its fragrant oil – could be a small step with big health benefits. This article is republished from The Conversation under a Creative Commons license. Read the original article. Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
New York Post
2 hours ago
- New York Post
People who eat certain type of diet are at low risk for dementia, research shows
Certain foods may feed the brain better than others. New research presented this week at NUTRITION 2025, the annual meeting of the American Society for Nutrition in Orlando, Florida, found that the MIND diet is particularly beneficial for cognitive health. Advertisement People who followed the MIND eating plan — which stands for Mediterranean-DASH Intervention for Neurodegenerative Delay — were 'significantly less likely' to develop Alzheimer's disease or other forms of dementia, according to a press release from the American Society for Nutrition. What is the MIND diet? MIND is a hybrid of the Mediterranean diet and the DASH diet (Dietary Approaches to Stop Hypertension), the latter of which is designed to reduce blood pressure. The diet focuses on 'brain-healthy foods' like leafy green vegetables, berries, nuts, and olive oil. 'The MIND diet is unique as the first eating plan focused on foods to specifically improve and support cognitive health,' Lauren Harris-Pincus, registered dietitian nutritionist and founder of and author of 'The Everything Easy Pre-Diabetes Cookbook,' told Fox News Digital. Advertisement 5 New research presented this week at NUTRITION 2025 found that the MIND diet is particularly beneficial for cognitive health. bit24 – 5 Those who followed the diet were shown to have an overall 9% reduced risk of dementia. LIGHTFIELD STUDIOS – The plant-focused MIND diet highlights 10 types of food, including berries, leafy greens, veggies, whole grains, nuts and seeds, beans, legumes, seafood, poultry, and olive oil, according to Harris-Pincus, who was not involved in the research. 'These focus foods contain nutrients that play a critical role in supporting brain health, including flavonoids, carotenoids, B vitamins, omega-3 fatty acids (especially DHA), choline, and minerals like magnesium, potassium, and calcium,' she said. Advertisement 'The diet also suggests limiting foods such as pastries, refined sugar, red meat, cheese, fried foods, fast food, and butter or margarine.' 5 The plant-focused MIND diet highlights 10 types of food, including berries, leafy greens, veggies, and whole grains. monticellllo – MIND's impact on brain health Researchers from the University of Hawaii analyzed data from nearly 93,000 U.S. adults who reported their dietary habits during the 1990s as part of the Multiethnic Cohort Study. At the start of the study, participants ranged in age from 45 to 75. Advertisement 5 People who followed the MIND eating plan were 'significantly less likely' to develop Alzheimer's disease or other forms of dementia, according to a press release from the American Society for Nutrition. Jacob Lund – In analyzing which participants developed Alzheimer's or other dementias in later years, the MIND eating plan performed better than other healthy diets in terms of reducing dementia risk, with benefits seen among both younger and older groups. Those who followed the diet were shown to have an overall 9% reduced risk of dementia, and some groups — African American, Latino, and White participants — showed a 13% lower risk. Asian-Americans and native Hawaiians did not show as pronounced a risk reduction. 5 'Our study findings confirm that healthy dietary patterns in mid to late life and their improvement over time may prevent Alzheimer's and related dementias,' said Song-Yi Park (not pictured), PhD, associate professor at the University of Hawaii at Manoa. LIGHTFIELD STUDIOS – The longer people adhered to the diet, the greater the reduction of risk. Those who followed the plan over a 10-year period had a 25% lower risk compared to those who didn't stick with it. 'Our study findings confirm that healthy dietary patterns in mid to late life and their improvement over time may prevent Alzheimer's and related dementias,' said Song-Yi Park, PhD, associate professor at the University of Hawaii at Manoa, in the release. 'This suggests that it is never too late to adopt a healthy diet to prevent dementia.'
Indianapolis Star
2 hours ago
- Indianapolis Star
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival – highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS) -a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. Werner Syndrome: A Rare and Devastating Accelerated Aging Disorder Werner Syndrome is a rare autosomal recessive disorder caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. Patients typically begin showing signs of premature aging-such as graying hair, cataracts, diabetes, osteoporosis, and atherosclerosis-in their 20s or 30s. Median life expectancy is 40-50 years. There are currently no FDA-approved treatments. To model this disease, the Company's study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which replicates key features of Werner Syndrome, including telomere loss, mitochondrial dysfunction, retinal degeneration, muscle deterioration, and abnormal DNA methylation. Key Preclinical Findings 1. DNA Methylation Reversal – Resetting the Genetic Clock DNA methylation is one of the body's key mechanisms for controlling which genes are turned on or off. It works by attaching small chemical tags (called methyl groups) to DNA at locations known as CpG islands -which act like gene 'on/off' switches. When methylation patterns are intact, cells know which genes to express and when. However, with aging and disease, this regulatory system starts to break down – a phenomenon known as epigenetic drift. In these cases, genes that should be off may turn on inappropriately, and protective genes may be silenced. This malfunction in gene regulation is strongly linked to a wide range of chronic diseases including: Cancer (via silencing of tumor suppressor genes) Neurodegenerative diseases like Alzheimer's and Parkinson's Autoimmune diseases such as lupus and multiple sclerosis Metabolic conditions like Type 2 diabetes Premature aging disorders like progeria and Werner Syndrome In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. 2. Telomere Elongation – Rebuilding the Chromosomal Clock Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, compared with the shortened length in the mutated animals, Telomir-1 increased telomere length by about three-fold. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting not only restoration but also potential enhancement of chromosomal integrity 3. Muscle Mass and Body Weight Recovery In the wrn-mutant zebrafish model, animals exhibited a 50-60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls – indicating functional recovery and metabolic improvement. 4. Oxidative Stress Reduction Reactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. 5. Survival Benefit Roughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1 treated groups – highlighting a systemic survival advantage. 'These results reinforce my conviction that Telomir-1 may represent one of the most important scientific developments in the field of aging,' said Erez Aminov, Chairman and CEO of Telomir. 'While we remain in the preclinical phase, the consistency and strength of the data demand serious attention. My full commitment is behind advancing Telomir-1 toward human studies in the most responsible and rigorous way. The potential here is too significant to ignore.' 'This is one of the most comprehensive rejuvenation profiles we've seen in a vertebrate aging model,' added Dr. Itzchak Angel, Chief Scientific Advisor. 'The ability to reverse both genomic and epigenetic instability while improving survival supports the growing potential of Telomir-1 as a foundational therapy for aging-related diseases.' Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information SOURCE: Telomir Pharmaceuticals, Inc View the original press release on ACCESS Newswire
